About Our Centre
Through the integration of clinical and basic science the Respiratory Medicine and Allergy Research Centre aims to develop, validate and implement novel methodologies for disease diagnosis, monitoring and prediction of outcomes. Our ultimate objective is to develop novel interventions for patient benefit in our themed areas, including strategies for disease prevention, pharmacological therapies and optimisation of interventions to reduce toxicity and the development of resistance, to allow the customisation of healthcare.
We have world-leading research and development in four main themes:
- Asthma and Food Allergy
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic cough
- Fungal Lung Disease
The research is based predominantly at the University Hospital of South Manchester (UHSM) with basic science teams based in the Manchester Institute of Biotechnology and the Core Technology Facility on the main University campus.
We host large, well-phenotyped patient cohorts, coordinated with biobanking, in all disease areas. We have the highest number of patients recruited in studies in respiratory medicine and allergy in the UKCRN portfolio; from 1 April 2008 to 12 December 2011, we recruited 4864 patients in respiratory studies in England, 19.4 per cent of the 25 090 patients recruited nationally).
Our Basic Science
The integration of basic biomedical science into the clinical research is enabling us to discover more about basic disease mechanisms. Our strong background in informatics and genetic epidemiology is enabling us to take a systems approach to studies spanning biomolecular science, microbiology and cell biology all set within the context of our clinical research and building on our cohorts.
Our Translational Research
Our integrated approach ensures that new ideas and approaches arising from our basic research are rapidly deployed in a clinical context.Our track record in early phase respiratory trials promises that our science innovation is rapidly translated into patient benefit. In the past 20 years, we have helped deliver 15 novel treatments to the market, with huge benefits to the UK economy, and to patients worldwide. We have developed a series of new tools and techniques such as cough monitors and food challenge materials for the objective measurement of outcomes.